# Expo Case completeness — WP2 CLOSED

**SHARED CLINICAL CATALOGUE + COMPLETE EXPO CASE CONTENT — CLOSED**

**EXPO MEDICAL REVIEW GATE — CLOSED**. Closure is the separate owner-authorized
implementation checkpoint, not production publication, media-rights clearance,
approved external RAG ingestion or JU/JUST curriculum approval.

Date: 2026-09-25. Baseline: `c57631b06ac193ac4522f91c44d770920cda9bf7`.

**BALSIM_CASE_COMPLETENESS_READY_FOR_OWNER_REVIEW — YES**

Medical review: **COMPLETE — APPROVED_FOR_EXPO**
Approval basis: **OWNER_ATTESTED_PHYSICIAN_REVIEW**
Reviewer role: **PHYSICIAN**
Reviewer identity: **NOT_FORMALLY_RECORDED**
Exact physician review timestamp: **NOT_FORMALLY_RECORDED**
Owner attestation: **CONFIRMED**
Expo execution: **APPROVED_EXPO / ALLOWED**
Production publication: **PENDING / NOT_PUBLISHED**

The owner attests that a qualified physician reviewed both complete current
medical datasets and confirmed their correctness. This is not a verified
physician identity/signature, a fabricated review date, or a production approval.
No attestation timestamp is substituted for the unknown physician review time.

No clinical values, patient facts, effects, action timing, scoring or patient assets
change in this approval correction. Source package lifecycle remains UNDER_REVIEW
as an **unpublished-package lifecycle**, not a pending medical-review decision.
The separate approval envelope is required for APPROVED_EXPO execution.

## Current immutable successors

| Patient | Version / version ID | Review execution hash | Review subject hash |
| --- | --- | --- | --- |
| Khalid | 2.4.0 / case-version.stemi.inferior-rv.006 | e212c36090b59a4d324348c85fd1f5f7a0dbff02b1710a4e360a135e060760d7 | 2e09cc954facbe91983decc60da03948ee0e012de8b16361e9b7d291f841386e |
| Dana | 1.5.0 / case-version.anaphylaxis.dana.006 | 0cc26e1bad72fd44f84afe9f11832789cc60fd8408c9b13e1276c9fbf2a0dd65 | bc2ea75e05a4c58f8ec6e4fea6e280190fca85dc3a1e8ed6753abbd8b7e51022 |

Both pin `catalogue.balsim.expo-clinical@1.1.0`: **33 shared concepts**:
14 investigations, 7 medication orders (6 drugs), 5 observations,
3 procedures, 3 supportive-care, 1 monitoring.

Khalid 2.3.0 and Dana 1.4.0 remain unchanged. Dana 1.3.0 and all earlier builders/hashes remain
unchanged. Dana 1.3.0 execution remains
`f844ec87eaf0d84c9cf530430e5c611bfd353413a4ae5f0f5e01d2c464c68072`.
Existing Sessions remain pinned. `npm run dev:wp2` starts the intended current
Khalid successor (4216); append `-- --patient=dana` for Dana (4217). Local review
host only with approved Expo semantics, no configured provider composition, fresh boot Session.

## Medical domains

COMPLETE means authored/inherited coverage exists, not approval. All original
review gates remain open. New content explicitly carries PENDING_PHYSICIAN_REVIEW.

| Domain | Khalid | Dana | Evidence / decision |
| --- | --- | --- | --- |
| A Patient profile | APPROVED_FOR_EXPO | COMPLETE | Existing 58-year-old male / adult female; no invented precise Dana age |
| B Presenting complaint | APPROVED_FOR_EXPO | COMPLETE | Existing pressure chest pain / itching, dizziness, dyspnea |
| C HPI | APPROVED_FOR_EXPO | COMPLETE | 55-minute continuous pain / 10–15 minutes after nut-containing dessert |
| D Past medical history | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Owner-authored chronic-disease/asthma negatives and prior mild reaction; no severe prior reaction/shock/admission/intubation |
| E Regular medicines | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Owner: no regular prescription medicines, beta-blocker, ACE inhibitor or antihistamine |
| F Allergies | APPROVED_FOR_EXPO | COMPLETE | Existing NKDA/contraindication screen / prior nut reaction; no new blanket NKDA |
| G Relevant family/social history | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Owner: family negatives, non-smoker/no vaping/drugs, bounded alcohol history, independent baseline |
| H ROS/patient knowledge | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Owner-supplied positive onset symptoms and pertinent negatives; history only in Patient Conversation |
| I Initial hidden physiology | APPROVED_FOR_EXPO | COMPLETE | Existing projections/state unchanged |
| J Acquired observations | APPROVED_FOR_EXPO | COMPLETE | All five WP1 pathways; no initial numeric-vital leakage |
| K General exam | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Existing appearance plus owner-authored alert/interactive/dizzy-not-collapsed baseline |
| K Airway exam | APPROVED_FOR_EXPO (limited authored scope) | APPROVED_FOR_EXPO | Khalid unchanged. Dana patent airway/mild lip edema and explicit owner-authored negatives |
| K Respiratory exam | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Existing bilateral wheeze/mild work retained; owner no unilateral reduced entry/tension-pneumothorax evidence |
| K Cardiovascular exam | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Existing tachycardia/hypotension; owner rapid reduced-volume pulse, refill about 3s, no edema |
| K Neurological/mental state | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Dana owner-supplied GCS15, orientation, command-following and focal-negative exam; no state-engine mutation |
| K Abdominal exam | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Owner-supplied soft/non-distended baseline, no focal tenderness/guarding/rebound/peritonism or active vomiting |
| K Skin exam | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Existing urticaria retained; owner mild lip swelling, no cyanosis/blistering/sloughing |
| K Extremities/perfusion exam | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Owner present reduced-volume pulses, refill about 3s; explicit limb edema/swelling/tenderness/DVT negatives |
| L Labs | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO | Eleven common panels; conflicting prior values preserved |
| M ECG/cardiac | APPROVED_FOR_EXPO + MEDIA_PENDING | APPROVED_FOR_EXPO + MEDIA_PENDING | Existing Khalid ECG/echo; owner-supplied Dana FoCUS added |
| N Imaging | APPROVED_FOR_EXPO + MEDIA_PENDING | APPROVED_FOR_EXPO + MEDIA_PENDING | Existing CXR text; media rights/review gates unchanged |
| O Special investigations | APPROVED_FOR_EXPO / search-only | APPROVED_FOR_EXPO / search-only; alternative value not adopted | Right ECG retained; tryptase sample/status retained, requested18 value held |
| P Medication/treatment | APPROVED_FOR_EXPO within existing authored scope | APPROVED_FOR_EXPO within existing authored scope | Fixed orders/consideration actions retained; no new prescribing engine |
| Q Procedures/support | APPROVED_FOR_EXPO | COMPLETE | IV/fluids/oxygen/monitor/escalation, exact prerequisites |
| R Treatment transitions | APPROVED_FOR_EXPO | COMPLETE | Khalid modest support/persistent pain; Dana staged improvement |
| S Diagnosis | APPROVED_FOR_EXPO | COMPLETE | Hidden Case facts and existing actions |
| T Disposition | APPROVED_FOR_EXPO | COMPLETE | Cath transfer endpoint; stabilization/observation/follow-up |
| U Scoring/evidence | APPROVED_FOR_EXPO | COMPLETE | Six-domain rubrics unchanged; new panels record evidence without invented points |
| V Visual response | APPROVED_FOR_EXPO; reperfusion extension not modeled | APPROVED_FOR_EXPO | Owner confirmed no invented PCI success. Dana rash/itch/swelling/calm follows improved flag |
| W Conversation facts | APPROVED_FOR_EXPO | APPROVED_FOR_EXPO for known subset | No new diagnostics, exam results, hidden diagnosis or rubric in patient knowledge |

No remaining MISSING core content domains. All new findings are baseline
medical content approved for Expo, not automatically acquired learner findings.
Exact HR/BP/RR/SpO2 still require WP1 acquisition. Examiner-only facts use
`after_exam` and are explicitly forbidden to Patient Conversation. Current visual
region selection does not itself commit an examination; expanded matching-action
findings delivery remains a separately documented integration limitation. This
authoring pass does not expose the new exam text through learner APIs at all.

## Final shared investigation coverage / central timing

Times are **SIMULATION_TIMING_FIXTURE**, clinical seconds after committed order,
not hospital turnaround claims. Every new order consumes15 clinical seconds.
Existing result/image/report timings remain distinct. Tests are not prerequisites
for urgent treatment. Exact collection, order and scheduled availability are
separate server fields. New lab results are fixed **BASELINE_CASE_SAMPLE t=0**;
the UI explicitly says they are not dynamic post-treatment measurements.

| Concept suffix | Khalid binding | Dana binding | Result delay K / D | Coverage |
| --- | --- | --- | --- | --- |
| cbc | investigation.cbc | investigation.complete.dana.cbc | 480 / 480 | explicit / explicit |
| electrolytes | investigation.complete.khalid.electrolytes | investigation.complete.dana.electrolytes | 480 / 480 | explicit / explicit |
| renal | investigation.complete.khalid.renal | investigation.complete.dana.renal | 480 / 480 | explicit / explicit |
| glucose | investigation.poc-glucose | investigation.complete.dana.glucose | 60 / 480 | explicit / explicit |
| troponin | investigation.hs-ctni | investigation.complete.dana.troponin | 600 / 600 |286ng/L ULN34 / qualitative negative |
| coagulation | investigation.coagulation | investigation.complete.dana.coagulation | 480 / 480 | explicit / explicit |
| blood-gas | investigation.complete.khalid.blood-gas | investigation.complete.dana.blood-gas | 180 / 180 | ABG / preserved VBG |
| lactate | investigation.complete.khalid.lactate | investigation.complete.dana.lactate | 180 / 180 |2.8 / preserved2.8 |
| liver | investigation.complete.khalid.liver | investigation.complete.dana.liver | 480 / 480 | explicit / explicit |
| crp | investigation.complete.khalid.crp | investigation.complete.dana.crp | 480 / 480 |4 /2mg/L |
| d-dimer | investigation.complete.khalid.d-dimer | investigation.complete.dana.d-dimer | 480 / 480 |0.35 /0.28mg/L FEU |
| ecg | investigation.ecg-standard | investigation.dana.ecg |120 /60 | authored inferior STEMI / sinus tachycardia |
| focused-echo | investigation.focused-echo | investigation.complete.dana.focused-echo |240 /240 | existing RV findings / owner-supplied hyperdynamic-underfilled LV |
| cxr | investigation.chest-xray | investigation.dana.cxr |300 /300 | existing explicit findings |

100% coverage: 28/28 common investigation bindings; 66/66 total shared bindings.
Both public shared catalogues are byte-identical. All earlier21 concepts survive.

Special searches: type at least3 characters in the existing Investigations search
(`right-sided` for Khalid; `tryptase` for Dana). These are explicitly case-specific
search-only choices, not shared first-level options. No opposite-case normal result
is fabricated. Their result cards appear only after order. Search metadata has no
result, diagnosis, score or correctness flag. An informed user can observe differing
special-test support on search; this is the owner-permitted special-test exception,
not a claim of identical whole-Session payloads.

Other legacy Case actions remain stored, including diagnosis/disposition/examination
actions not in this bounded shared set. Full learner workflow exposure of those
actions is not implemented by this investigation correction and must not be claimed.

## Preserved conflicts / owner decisions

| Field | Existing value preserved | New target held |
| --- | --- | --- |
| Khalid CBC WBC/Hb/Hct/platelets |9.1 /14.3 /43 /238 |10.8 /14.1 /42 /230 |
| Khalid Cl/BUN/glucose |102 /22 /184 |101 /32 /178 |
| Khalid troponin |hs-cTnI286ng/L, ULN34 |4.80ng/mL =4800ng/L; not equivalent |
| Dana CBC WBC/Hb/platelets |8.5 /13 /250 |11.2 /13.4 /265 |
| Dana K/glucose |4.0 /112 |3.8 /132 |
| Dana gas |VBG7.34 /36 /19 |ABG7.46 /30 /21 /PaO2 69; venous PO2 not invented |
| Dana lactate |2.8 |2.6 |
| Dana tryptase |sample sent; assay result pending beyond encounter |18µg/L during encounter |
| Khalid post-support face |persistent pain retained |Resolved by owner: no generic pain disappearance; no PCI-success state invented |

Dana FoCUS is now explicitly supplied by the owner: hyperdynamic, underfilled LV,
preserved global systolic function; no focused RWMA, RV dilatation/strain or
pericardial effusion; small collapsible IVC; no gross structural abnormality.
No precise EF. Limited bedside study, not comprehensive echocardiography.

Dana history/examination decision: no conflict with the existing authored fields
was found. All old facts/localization, action definitions, results, rules, rubric,
physiology and visual modules remain byte-equivalent (except the required new
PatientState case-version pin). Alcohol retains the owner's "none or occasional
only; no relevant recent intake" wording without invented quantity/frequency.
No additional age, weight, pregnancy history, severe airway findings, collapse,
severe GI symptoms, animation or treatment effect was authored.

## Reference configuration and provenance

`balsim.simulation-reference-bands.v1` is local **APPROVED_FOR_EXPO simulation display configuration**.
WBC3.4–9.6, male Hb13.2–16.6/Hct38.3–48.6 and female Hb11.6–15/Hct35.5–44.9 are
informed by [Mayo's adult CBC catalogue](https://mml.testcatalog.org/show/CBC).
Platelet150–400 is an explicit simulation band, not attributed to Mayo.
Other bands are declared in `medical-dataset.ts`, not universal or guideline-issued
limits. No critical thresholds inferred. No fasting glucose claim. Dana eGFR>90
retains a structured GREATER_THAN qualifier. eGFR is supplied, not calculated using
an invented age. Negative Dana troponin is qualitative; assay-specific numeric
numeric cutoff is not supplied or inferred. Khalid's existing hs-cTnI assay/ULN is preserved.

Reference metadata only; no documents ingested into trusted RAG:

- [2025 ACC/AHA ACS guidance](https://professional.heart.org/en/science-news/2025-guideline-for-the-management-of-patients-with-acute-coronary-syndromes/top-things-to-know): ACS treatment structure; existing orders remain primary.
- [2023 ESC ACS guideline](https://academic.oup.com/eurheartj/article/44/38/3720/7243210): diagnostic/reperfusion structure. Laboratory completion must not delay indicated reperfusion.
- [RCUK anaphylaxis guideline](https://www.resus.org.uk/sites/default/files/2021-05/Emergency%20Treatment%20of%20Anaphylaxis%20May%202021_0.pdf): urgent resuscitation; investigations may support care but must not delay it. Acute tryptase and later baseline are different samples.
- [WAO2020 guidance, published article](https://doi.org/10.1016/j.waojou.2020.100472), read via [Allergy Society of South Africa hosted copy](https://allsa.org/wp-content/uploads/2021/08/WAO-Anaphylaxis-2020.pdf): IM epinephrine first-line, follow-up/prevention; normal tryptase does not exclude anaphylaxis.
- [2023 Anaphylaxis Practice Parameter](https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Allergist%20Resources/Statements%20and%20Practice%20Parameters/Anaphylaxis-Practice-Paramaters-2023.pdf): context-sensitive tryptase interpretation and baseline comparison.

Exact added numbers/FoCUS wording are owner-authorized synthetic content. None of
these sources prescribe those exact patient-specific values. All remain unresolved
for formal source approval/trusted educational retrieval, not current medical review. No copyrighted full guideline was copied.

## Media audit

Scoped READ-ONLY `C:\Diagnostic Library` ECG report search: ECG-002 states84bpm;
ECG-003 anterior88, ECG-004 anterolateral92 are not substitutes. No traced
inferior110–115 candidate found. Nested ECG-002 report is empty. No source library
file changed or new media copied. New Khalid runtime shows authoritative text and
`ECG_MATCHED_IMAGE_PENDING_PHYSICIAN_REVIEW`, not the mismatched image.
CXR review/rights gate remains open. Right ECG/FoCUS/Dana images remain pending.

## Review handoff / prior verification history

- `KHALID_COMPLETE_CASE_REVIEW.md`: whole authored case, all results, legacy actions,
  transitions, scoring, patient-known facts and APPROVE/CHANGE/COMMENT fields.
- `DANA_COMPLETE_CASE_REVIEW.md`: same, with all owner-authored history/exam fields
  and per-fact provenance; old missing-field blocker is resolved.
- `node v2/scripts/wp2-case-review-export.mjs` prints a deterministic read-only export
  (JSON containing Markdown); it never writes/approves content or calls providers.
- Prior correction verification: 628 distinct Browser tests across main run/targeted
  rechecks (current completeness 46/46; diagnostic API 6/6), 19/19 Deno,
  12/12 Node, 2/2 actual-App scenarios; typecheck/build/portability/secret scan/
  diff check PASS. See [WP2 handoff](../uiux/WP2_SHARED_CLINICAL_CATALOGUE.md)
  for run qualifications and actual-App evidence paths.
- End-of-Session disclosure cannot bypass committed order/component availability.
  Foreign/future/unordered result receipts cannot mark inventory AVAILABLE.
- Both physician packs were compared with the read-only Case export and match.
- Prior correction scoped WIP: 17 modified tracked + 23 new files; zero staged. Prior WP2
  work preserved. Disposable test failures moved recoverably into ignored results.
- Owner-decision follow-up: 352/352 focused Browser tests (including 14 new Dana
  checks), 12/12 Deno, 12/12 Node and 2/2 actual-App scenarios PASS. Typecheck,
  build, portability and secret scan PASS; existing bundle-size warning only.
  Actual-App runs assert Khalid 2.3.0 / Dana 1.4.0 review pins. Both packs match
  the current read-only export. Current scoped WIP: 17 modified tracked + 26 new
  files = 43, zero staged; the previous WIP is preserved.
- Final `git diff --check` and whitespace checks on all 26 scoped untracked files
  PASS. Only non-executable handoff documentation changed after verification.
- No commit/push, no WP3, no final UI, no provider requests, no asset/lab/V1/ADR edits.

## Approval correction audit

The earlier verification/history counts above describe their original trees.
Current approval verification is recorded in
[OWNER_ATTESTED_EXPO_APPROVAL.md](OWNER_ATTESTED_EXPO_APPROVAL.md).

Preserved parent execution hashes:

- Khalid 2.3.0: `1628d4fe87490fa4064c53b210dfc5a2380508ad66e11d55c6d1697aaafc1b74`.
- Dana 1.4.0: `f468a31839af399b02b401aa5dde002d7ffc90d5da34026e3a8bb559a4084926`.

Existing Sessions remain bound to their old version/authority. Approval does not
upgrade an already-running historical review Session. Restart the intended WP2
review host to create a new approved Expo Session. Legacy V2 review hosts keep
their historical pins; they are not implicitly promoted.

Requested conflicting replacements in the table above remain **not adopted**.
The approved dataset is the exact existing-value column. A later medical change
requires a new immutable successor and new content-bound approval.
